Lionel H. Opie

These important agents are now established therapy for two of the most common cardiological conditions--hypertension and congestive heart failure. Using an objective, comprehensive approach it provides essential, detailed information on the clinical application of ACE inhibitors. Answers such questions as which agents are best tested; what do the numerous and sometimes conflicting trials say; when can ACE inhibitors benefically be combined with other antihypertensives; which doses should be used and much more.

Angiotensin-Converting Enzyme Inhibitors

Stunning is potentially an important complication of myocardial reperfusion. In contrast, hibernation is an important complication of myocardial ischemia. This book presents different viewpoints on these subjects, taken from a series of peer-reviewed articles which first appeared in Cardiovascular Drugs and Therapy, and now in this book. In addition, a certain number of articles were directly invited for the book. The introductory article is by Eugene Braunwald, who with Kloner introduced the term myocardial stunning in 1982. The experimental phenomenon had first been described by Heyndrickx et al. This important concept of stunning is examined from a number of points of view in a series of articles which clarify the experimental causes and the clinical implications. The section on hibernation is introduced by Tubau and Rahimtoola, the latter having first propounded the concept in 1989. The difference between stunning and hibernation is that stunning is essentially a post-ischemic dysfunction of the myocardium, temporary in nature, occurring at a time when coronary blood flow is apparently normal or supranormal. Hibernation, on the other hand, is a condition of reduced contractile activity, the direct result of chronic ischemia and hence a sign of a tolerable reduction in blood flow. Possibly the reduction in contractile activity of the hibernating heart balances the reduction in the oxygen availability (the `smart heart' of Rahimtoola). This non-contractile heart is hibernating, awaiting the return of summer after winter, and willing to contract normally again whenever warm coronary blood is restored. It is certain that the concepts of stunning and hibernation are here to stay, that they have or will have clinical relevance, and that the search for the most appropriate diagnosis and therapy for each condition is now under way. Hence, a greater understanding of the experimental work which underlies these two conditions is highly appropriate.

Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion

Bernard J. Gersh

Drugs for the Heart presents highly portable, up-to-date information on every drug class used to treat cardiovascular disease. Drs. Lionel H. Opie and Bernard J. Gersh put the latest dosages, interactions, indications and contraindications, side effects, and more at your fingertips, equipping you to make effective clinical decisions on behalf of your patients Quickly check when to use each drug for any condition with the popular "Which Drug for Which Disease" chapter. Get expert advice from the practice-proven experience of two well-known editors who represent the best possible combination of clinical and research expertise in cardiovascular therapeutics. Expedite your reference with summaries of each drug class at the end of chapters. Carry it with you anywhere thanks to a highly compact, pocket-sized format. Navigate the latest pharmacologic advances through coverage of the newest drugs and drug classes, as well as all the latest clinical trial results and evidence used to treat heart disease. Effectively manage comorbid diseases. Apply international insights into cardiac drugs, thanks to new global contributors. Visualize key pharmacologic and physiologic actions thanks to dynamic new full-color drawings. Access the complete contents online at Expert Consult, with regular online updates posted by leading cardiologist, Dr. Opie. Your purchase entitles you to access the web site until the next edition is published, or until the current edition is no longer offered for sale by Elsevier, whichever occurs first. If the next edition is published less than one year after your purchase, you will be entitled to online access for one year from your date of purchase. Elsevier reserves the right to offer a suitable replacement product (such as a downloadable or CD-ROM-based electronic version) should access to the web site be discontinued.

Expert Consult - Online and Print

Drugs for the Heart

Aimed at those who strive for optimal long-term health and the maximal functioning of their hearts and minds, 'Living Longer' sifts through the often conflicting information available on the vast number of possible health promotion changes. It isolates five key steps to promote long-term health benefits for the heart and mind.

Exploring the Heart-Mind Connection

Living Longer, Living Better

Calcium antagonists are now regarded as the most important advance in cardiac drug therapy since the advent of beta-adrenergic blocking agents. Acting ba sically as vasodilators-though with many other com plex mechanisms especially in the case of the anti arrhythmic calcium antagonists, these agents have grown in importance to become among the therapeutic agents of first choice for angina pectoris and hyper tension. The major aim of the present book is to present the clinician with the information needed for the practical use of calcium antagonists. What do all the numerous and often conflicting trials say? Do these agents really work? If so, which agent and in what dose? How do the three front runners, verapamil, nifedipine and diltia zem compare in the efficacy and side-effects with each other? How do the new second generation agents, now entering the North American market, slot in and com pare with the three first-liners? When the gloss is taken away from the advertisements, what is really left? The strong clinical bias of the present book should be complimented by further reading of books slanted towards fundamentals. One of the most important and recent of these is that by Dr Winifred Nayler (Calcium Antagonists, Academic Press, 1988). That book should be basic for essential background knowledge in the area of calcium antagonists. The important basic contribu tions of Fleckenstein deserve emphasis.

Clinical Use of Calcium Channel Antagonist Drugs

An international cast of cardiologists now brings you DRUGS FOR THE HEART, 5th Edition. This New Edition is the definitive pocket-sized practitioner's guide to the complexities of cardiovascular drug therapy. Completely updated and with even more and better illustrations than ever, it presents the latest evidence-based information in the field. Staightforward, concise information on the appropriate doses and choices for a range of cardiac conditions Updated entries and illustrations reflect today's expertise on the subject An added management chapter in each section - which improves the clinical utility of the book New design makes information easy to access

This straightforward, concise guide offers information on the appropriate drug choices and doses for a range of cardiac conditions. The updated illustrations reflect today's expertise on the subject.

Lionel H. Opie

About

Books

Join the club